Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135997 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL344610 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL503691 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL8014762 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL851632 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL18107094 | 0.78 | SLC6A2 (0.47) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL11785888 | 0.78 | SLC6A2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL8725722 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL206553 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 | |
| SCHEMBL27908890 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1ASLC6A2TAAR1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953625-A1 | NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150353530-A1 | NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | CORTENDO AB (PUBL) (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014122530-A1 | NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | CORTENDO AB (PUBL) (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2011076784-A2 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-30 | — | — | WO | disclosed |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | VERNALIS RESEARCH LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-6335324-B1 | TREATING ASTHMA OR ALLERGIC RHINITIS | BRISTOL-MYERS SQUIBB CO. | 2002-01-01 | — | — | US | disclosed |
| EP-1089973-A4 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1089973-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067215-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0611776-A2 | New pseudopeptides with antiviral activity | BAYER AG (DE) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353530-A1 | NOVEL FUNCTIONALIZED 4-(PHENOXYMETHYL(-1,3-DIOXOLANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | CYP11B1, CYP11B2, CYP21A2 | SMN1; SMN2 3722/4885HIF1A 1183/4885SLC6A2 1255/4885 |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | CNR1, CNR2, GPR119 | SMN1; SMN2 1780/4885HIF1A 1932/4885SLC6A2 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.